We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.19 | 4.03% | 4.90 | 4.89 | 4.94 | 4.94 | 4.6895 | 4.84 | 4,668,267 | 00:52:22 |
1. Name and Address of Reporting Person * Herrmann John A III | 2. Issuer Name and Ticker or Trading Symbol NOVAVAX INC [ NVAX ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP, Chief Legal Officer |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 2/1/2021 | M(1) | 394 | A | $27.00 | 669 | D | |||
Common Stock | 2/1/2021 | M(1) | 2214 | A | $27.00 | 2883 | D | |||
Common Stock | 2/1/2021 | M(1) | 2085 | A | $27.60 | 4968 | D | |||
Common Stock | 2/1/2021 | M(1) | 2080 | A | $46.00 | 7048 | D | |||
Common Stock | 2/1/2021 | M(1) | 8249 | A | $5.95 | 15297 | D | |||
Common Stock | 2/1/2021 | S(1) | 1443 | D | $239.0421 (2) | 13854 | D | |||
Common Stock | 2/1/2021 | S(1) | 4294 | D | $240.4282 (3) | 9560 | D | |||
Common Stock | 2/1/2021 | S(1) | 3331 | D | $241.5067 (4) | 6229 | D | |||
Common Stock | 2/1/2021 | S(1) | 2200 | D | $242.1968 (5) | 4029 | D | |||
Common Stock | 2/1/2021 | S(1) | 3754 | D | $243.25 | 275 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Option (Right to Buy) | $27.00 | 2/1/2021 | M (1) | 394 | (6) | 11/14/2026 | Common Stock | 394 | $0.00 | 0 | D | ||||
Stock Option (Right to Buy) | $27.00 | 2/1/2021 | M (1) | 2214 | (7) | 11/14/2026 | Common Stock | 2214 | $0.00 | 0 | D | ||||
Stock Option (Right to Buy) | $27.60 | 2/1/2021 | M (1) | 2085 | (8) | 12/15/2027 | Common Stock | 2085 | $0.00 | 4592 | D | ||||
Stock Option (Right to Buy) | $46.00 | 2/1/2021 | M (1) | 2080 | (9) | 12/13/2028 | Common Stock | 2080 | $0.00 | 9591 | D | ||||
Stock Option (Right to Buy) | $5.95 | 2/1/2021 | M (1) | 8249 | (10) | 9/26/2029 | Common Stock | 8249 | $0.00 | 66001 | D |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Herrmann John A III C/O NOVAVAX, INC. 21 FIRSTFIELD ROAD GAITHERSBURG, MD 20878 | EVP, Chief Legal Officer |
Signatures | ||
/s/ John A. Herrmann III | 2/3/2021 | |
**Signature of Reporting Person | Date |
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions